Erasca, Inc.
ERAS
Rang în acțiuni
#3566
Erasca, Inc. is a biopharmaceutical company in the clinical development stage,... Erasca, Inc. is a biopharmaceutical company in the clinical development stage, primarily focused on identifying, advancing, and commercializing therapeutic solutions for malignancies propelled by the RAS/MAPK pathway. The firm's pipeline features several key experimental drugs: ERAS-007, an orally administered ERK1/2 inhibitor designed to address non-small cell lung cancer, colorectal cancer, and acute myeloid leukemia; and ERAS-601, an oral SHP2 inhibitor targeting patients with advanced or metastatic solid tumors. Additionally, Erasca is progressing ERAS-801, an EGFR inhibitor capable of penetrating the central nervous system, intended for recurrent glioblastoma multiforme. The company was founded in 2018 and maintains its headquarters in San Diego, California.
Preț acțiune
$13.68
Ultima sincronizare: 2026-10-19
Capitalizare de piață
$4.78B
Schimbare (1 zi)
2.13%
Schimbare (1 an)
455.89%
Țară
US
Tranzacționează Erasca, Inc. (ERAS)
Categorie
Healthcare
Raport P/S pentru Erasca, Inc. (ERAS)
Raport P/S la data de October 2026 TTM: 0.00
Conform celor mai recente rapoarte financiare și prețului acțiunilor Erasca, Inc., raportul P/S actual (TTM) este 0.00. La sfârșitul anului 2023, compania avea un P/S de 0.00.
Istoricul raportului P/S pentru Erasca, Inc. din 2019 până în 2026
Raport P/S la sfârșitul fiecărui an
| An | Raport P/S | Schimbă |
|---|---|---|
| 2026 (TTM) | 0.00 | 0.00% |
| 2024 | 0.00 | 0.00% |
| 2023 | 0.00 | 0.00% |
| 2022 | 0.00 | 0.00% |
| 2021 | 0.00 | 0.00% |
| 2020 | 0.00 | 0.00% |
| 2019 | 0.00 | 0.00% |
Raport P/S pentru companii similare sau competitoare
| Companie | Raport P/S | Diferență raport P/S | Țara |
|---|---|---|---|
| 10.02 | - |
US
|
|
| 40.55 | - |
US
|
|
| 3.96 | - |
AU
|
|
| - | - |
CH
|
|
| 10.15 | - |
NL
|
